MS CONTIN Drug Patent Profile

When do Ms Contin patents expire, and what generic alternatives are available?

Ms Contin is a drug marketed by Purdue Pharma Lp and is included in one NDA.

The generic ingredient in MS CONTIN is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ms Contin

A generic version of MS CONTIN was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for MS CONTIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Patent Applications:	4,355
Drug Prices:	Drug price information for MS CONTIN
What excipients (inactive ingredients) are in MS CONTIN?	MS CONTIN excipients list
DailyMed Link:	MS CONTIN at DailyMed

See drug prices for MS CONTIN

See drug sales revenues for MS CONTIN

Recent Clinical Trials for MS CONTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University Innsbruck	Phase 2
National Institute of Nursing Research (NINR)	Phase 4
Ranbaxy Inc.	Phase 1

See all MS CONTIN clinical trials

Pharmacology for MS CONTIN

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

US Patents and Regulatory Information for MS CONTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-003	Sep 12, 1989	AB	RX	Yes	No
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-004	Jan 16, 1990	AB	RX	Yes	Yes
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-001	May 29, 1987	AB	RX	Yes	No

Expired US Patents for MS CONTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-003	Sep 12, 1989
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-005	Nov 8, 1993
Purdue Pharma Lp	MS CONTIN	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019516-004	Jan 16, 1990

International Patents for MS CONTIN

See the table below for patents covering MS CONTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Czechoslovakia	228142	PREPARATION OF MOLECULAR COORDINATING COMPLEX
Spain	8303489
Netherlands	8006891

Market Dynamics and Financial Trajectory for MS CONTIN

Last updated: July 28, 2025

Introduction

MS CONTIN, a sustained-release oral formulation of morphine sulfate, has established itself as a critical component in managing severe chronic pain, especially in palliative care and cancer pain management. Its market trajectory and financial outlook are shaped by multifaceted factors, ranging from regulatory shifts and patent landscapes to evolving clinical practices and competitive innovations. Navigating these dynamics offers insights for stakeholders aiming to optimize investments and strategic positioning within this segment.

Market Overview and Key Drivers

The global pharmaceutical market for opioid-based analgesics, including MS CONTIN, is anticipated to grow steadily, driven by rising prevalence of chronic pain conditions and aging populations. According to reports, the global pain management market is projected to reach USD 96.3 billion by 2027, growing at a CAGR of approximately 5.9% [1]. Morphine-based formulations, especially sustained-release variants like MS CONTIN, constitute a significant portion owing to their proven efficacy in long-term pain control.

Clinical and Regulatory Influences

Clinical guidelines, notably guidelines from the World Health Organization (WHO) and various national agencies, often endorse opioids like MS CONTIN for severe pain, bolstering demand. However, intensifying regulatory scrutiny, especially concerning opioid misuse and abuse, introduces new hurdles. In the U.S., for instance, the DEA’s scheduling and strict prescription regulations have affected prescribing patterns [2].

The implication for MS CONTIN is twofold: while regulations constrict supply chains and prescribing, they simultaneously encourage the development of abuse-deterrent formulations and alternative delivery systems, which could threaten or complement traditional MS CONTIN sales.

Patent and Competitive Landscape

The patent life of MS CONTIN significantly impacts its financial trajectory. Purdue Pharma, the original manufacturer, held patent protections that enabled premium pricing until patent expiry in multiple regions, leading to anticipated revenue drops due to generic competition post-patent expiration (around 2017-2018 in the U.S.) [3]. Generic versions have since entered the market, exerting downward pressure on prices and revenues.

Emerging competitors are innovating with abuse-deterrent formulations and novel delivery platforms such as transdermal patches or implantable implants. These introduce competition that could erode MS CONTIN’s market share if they demonstrate superior safety, efficacy, or convenience.

Market Penetration and Geographic Trends

Geographically, the North American market represents a substantial share owing to high opioid utilization and advanced healthcare infrastructure. Europe follows with increasing acceptance of opioid-based analgesics but is more cautious due to opioid-related concerns. Emerging markets in Asia-Pacific show promising growth due to rising healthcare investments, aging populations, and improvements in pain management standards.

Financial Trajectory and Revenue Projections

Historically, MS CONTIN contributed millions of dollars in revenue for its manufacturers. Post-patent expiration, revenues declined in key markets, but niche applications and ongoing clinical use sustain a baseline. The introduction of newer formulations and combination therapies could reshape this trajectory, either offsetting declines or capturing new segments.

Analysts forecast that, barring disruptive factors, the market for MS CONTIN and similar formulations will experience moderate growth due to increased demand for long-acting opioids. However, the trajectory is tempered by the shift towards multi-modal pain management strategies reducing opioid reliance, and by regulatory pressures.

Impact of Regulatory and Societal Changes

A pivotal factor influencing the financial outlook is the ongoing societal response to the opioid epidemic. Stricter regulations aim to curb misuse but inadvertently affect legitimate pain management, influencing sales volumes and pricing strategies. Companies invested in MS CONTIN must adapt through patient-centric formulations, risk mitigation strategies, and diversification into alternative therapies [4].

Innovation and Future Opportunities

Innovators are exploring abuse-deterrent formulations, implantable devices, and combination therapies that could redefine pain management paradigms. The integration of digital health, real-time monitoring, and personalized medicine could further influence the financial prospects of traditional formulations like MS CONTIN.

Conclusion

The market dynamics for MS CONTIN are complex and subject to rapid change. While demand remains steady in specific segments, legal, competitive, and social forces impose constraints. Companies that invest in innovation, leverage regulatory insights, and expand into emerging markets will better position themselves to capitalize on future growth avenues. Stakeholders should monitor evolving clinical guidelines and societal attitudes towards opioids to refine their investment and strategic plans.

---

Key Takeaways

• The global pain management market, including MS CONTIN, is projected for steady growth, driven by demographic trends and chronic pain prevalence.
• Patent expirations and generic competition have historically reduced revenues, necessitating innovation and differentiation.
• Regulatory scrutiny and societal concerns over opioid misuse influence prescribing patterns and market dynamics.
• Emerging technologies, including abuse-deterrent formulations and digital health integrations, offer potential growth opportunities.
• Geographic expansion into emerging markets could mitigate declines in mature regions, provided regulatory and cultural barriers are addressed.

---

FAQs

1. How has patent expiration affected MS CONTIN’s market share?
Patent expiration led to the entry of generic competitors, significantly reducing MS CONTIN’s pricing power and revenue in developed markets like the U.S. and Europe, prompting manufacturers to innovate or diversify their product portfolios.

2. What regulatory challenges does MS CONTIN face globally?
Across jurisdictions, stricter opioid regulations, prescription monitoring programs, and abuse-deterrent requirements have limited prescribing and sales, requiring companies to adapt through product reformulation and compliance strategies.

3. Are there any significant innovations threatening MS CONTIN’s market position?
Yes, abuse-deterrent formulations, transdermal delivery systems, and implantable devices are emerging as alternatives, offering potentially safer and more convenient options, which could challenge traditional MS CONTIN sales.

4. What regions are emerging markets for long-acting opioid formulations?
The Asia-Pacific region, Latin America, and some Middle Eastern countries present growth opportunities due to expanding healthcare infrastructure, increasing pain management needs, and rising income levels.

5. How might societal attitudes toward opioids influence the future market for MS CONTIN?
Heightened awareness of opioid misuse may lead to tighter regulation, reduced prescribing, and a shift towards non-opioid pain therapies, threatening long-term demand for MS CONTIN.

---

References

[1] MarketsandMarkets, "Pain Management Market by Drug Class, Application, and Region – Global Forecast to 2027," 2022.

[2] U.S. Drug Enforcement Agency (DEA), "Prescription Drug Monitoring Program," 2023.

[3] Purdue Pharma, "Patent Portfolio and Market Exclusivity," Corporate Reports, 2018.

[4] World Health Organization, "Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain," 2018.